“Decline in physical function (PF) is associated with pretreatment depressive symptoms, decreased mobility, more pain, and dyspnea in older cancer patients referred for systemic cancer treatment”

Magnus Harneshaug 1,2, Lene Kirkhus 1,2, Jūratė Šaltytė Benth 1,3,4
Bjørn Henning Grønberg 5,6, Sverre Bergh 1,7, Siri Rostoft 2,8, Marianne Jensen Hjermstad 10,11, Marit S. Jordhøy 1,2,9

1 The Research Centre for Age Related Functional Decline and Diseases, Innlandet Hospital Trust 2 Institute of Clinical Medicine, Faculty of Medicine, University of Oslo 3 Health Services Research Unit, Akershus University Hospital 4 Institute of Clinical Medicine, Campus Ahus, University of Oslo 5 The Cancer Clinic, St. Olav’s Hospital, Trondheim University Hospital 6 Department of Clinical and Molecular Medicine, NTNU, Norwegian University of Science and Technology 7 Norwegian Advisory Unit on Aging and Health, Vestfold Hospital Trust 8 Department of Geriatric Medicine, Oslo University Hospital 9 The Cancer Unit, Innlande hospital trust, 10 Regional Advisory Unit for Palliative Care, Dept. of Oncology, Oslo University Hospital 11 European Palliative Care Research Centre (PRC), Department of Oncology, Oslo University Hospital
Methods:

- **288 patients included**
- **GA**
  - Comorbidities
  - Polypharmacy
  - Nutritional status
  - Cognitive function
  - Depressive symptoms
  - Mobility
- **PF and symptom-scores**
Trajectory Analyses to Identify Distinct Subgroups of PF Development

Belonging to the poor group was independently associated with:

- More depressive symptoms
- Decreased mobility
- More pain
- More dyspnea

91.5
68.3
51.6
92% alive after 6 months
84% alive after 6 months
62% alive after 6 months